A Novel Signature of Disulfidptosis‐Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Genomics
- Vol. 2025 (1)
Abstract
Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis‐related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival outcomes. Functional enrichment and immune‐related analyses revealed that the high‐risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune‐related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high‐risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81672968)
This publication has 61 references indexed in Scilit:
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosisActa Neuropathologica, 2013
- Structure and function of long noncoding RNAs in epigenetic regulationNature Structural & Molecular Biology, 2013
- Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MGMolecular Biology Reports, 2012
- Impact ofEGFRGenetic Variants on Glioma Risk and Patient OutcomeCancer Epidemiology, Biomarkers & Prevention, 2011
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiformeNeuro-Oncology, 2011
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- Noncoding RNAs and RNA Editing in Brain Development, Functional Diversification, and Neurological DiseasePhysiological Reviews, 2007
- The Transcriptional Landscape of the Mammalian GenomeScience, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005